Power3 Presents at Breast Cancer Symposium

Dr. Essam Sheta of Power3 Medical Presents Poster at The San Antonio Breast Cancer Symposium

Poster Details Power3’s Early Detection Test For Breast Cancer

Houston, TX -- Power3 Medical Products, Inc. (OTCBB: PWRM), a leading proteomics company specializing in the development and commercialization of diagnostic tests for the early detection of breast cancer and neurodegenerative diseases, presented a scientific poster at the San Antonio Breast Cancer Symposium. Dr. Essam Sheta, one of the authors of the poster, a Director of Power3’s CLIA laboratory and Director of Biochemistry, presented the poster for the company.

In the poster entitled “Discovery of Serum Biomarkers For Breast Cancer Detection,” Dr. Sheta, et al. discuss the urgent need for objective diagnostic tests to detect breast cancer in its earliest stages. The poster exemplifies the diagnostic power of biomarkers that are extremely powerful to both physicians and patients. Power3’s analyses of blinded samples have confirmed the validity of these biomarkers for use in diagnostics.

“Our poster at the San Antonio Breast Cancer Symposium provided an excellent arena for us to display our progress with the test for the early detection of breast cancer,” commented Steve Rash, Chief Executive Officer of Power3 Medical. “The validity of our biomarkers for use in diagnostics has been confirmed through our studies and we were honored to have this opportunity to demonstrate our results.”

About Power3 Medical Products

Power3 Medical Products, Inc. (OTCBB: PWRM), is a leading proteomics company engaged in the commercialization of protein biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets for cancer and neurodegenerative diseases. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 has signed its first distribution agreement to provide its blood serum diagnostic for breast cancer, BC-SeraPro, in twelve Middle Eastern countries before the end of 2007. Power3 operates a state-of-the-art CLIA certified proteomics laboratory in The Woodlands (Houston), Texas, and recently announced an agreement forming a joint venture (CRO) with NeoGenomics, Inc. (NASDAQ: NGNM - News) of Fort Myers, Florida, to commercialize Power3’s portfolio of IP, centering on the 543 biomarkers the Company has discovered from a broad range of diseases as the basis of blood-based tests for breast cancer, ALS, Alzheimer’s, and Parkinson’s Diseases.